$ORCL

The Oracle Stock Question Wall Street Will Be Asking for Years

Oracle (ORCL) stock has fallen 53% over 12 months despite strong AI growth. 24/7 Wall St. sets a $217.95 price target, citing Q1 revenue of $19.345B (+29.61% YoY) and a $664B backlog. Bulls highlight AI contracts and capacity, while bears point to negative free cash flow and high capex. ORCL trades at a lower forward P/E than MSFT and IBM with higher growth.

Original reporting
Published Sep 18, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 2:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
The Oracle Stock Question Wall Street Will Be Asking for Years — source image
Decision brief

The 30-second read

$ORCLBullishHigh
01

Why it matters

The earnings beat and guidance lift the stock's upside thesis, but cash burn and capex remain key risks.

02

Market read

Oracle's results could drive a sector‑wide rally in AI infrastructure providers and influence investor sentiment toward cloud software stocks.

03

What to watch

Potential supply‑chain constraints for GPUs and the impact of rising interest expense on debt financing costs.

Relevance 9/10Novelty 9/10Timing: post‑earnings today

Background

Oracle reported a standout Q1 FY2027 with record AI contract wins and raised long‑term revenue guidance.

Company-level read

Ticker impact

$ORCLBullishHigh confidence
Context

Q1 FY2027 earnings released Sep 10 show revenue of $19.345B (+29.6% YoY) and raised FY2027 revenue guidance to at least $90B.

Expected impact

Potential rally toward the $217 target price over the next 12 months.

Evidence & confidence

Revenue beat, massive AI backlog conversion, and higher guidance outweigh near‑term cash burn concerns.

Market effects

Oracle's AI infrastructure growth could lift the broader enterprise cloud and AI hardware sector.

Positive for U.S. tech equities, especially peers in AI and cloud services.

Highlights the accelerating shift to AI‑driven enterprise spend worldwide.

Counterpoint

High capex and negative free cash flow may pressure margins, risking a pullback if execution stalls.

Key entities

  • Larry Ellison

    Cancelled a planned $7.5B stock sale, signaling insider confidence.

  • Hilary Maxson

    CFO who highlighted free‑cash‑flow conversion assumptions.

Related articles

$ORCLMed

Why Oracle (ORCL) Stock Is Trading Lower Today

Oracle (ORCL) shares fell 3.4% after reports of internal AI struggles, including high costs and software issues. The stock later recovered slightly to $145.59, down 3.3%. Oracle has seen significant volatility, with a 25.6% year-to-date decline and a 55.6% drop from its 52-week high. The company's shares have gained 69% over five years.

$CRWVHighAI 8/10

Oracle, CoreWeave Dump on AI's $3.6 Trillion Financing Bill - Oracle (NYSE:ORCL)

CoreWeave (CRWV) shares fell 4% after announcing a $3B convertible debt raise, with an option for $500M more. Sona Asset Management research highlights CoreWeave and Oracle (ORCL) as highly leveraged in the AI supply chain. Oracle has $125.3B in borrowings and $288B in future data-center leases. CoreWeave has $35.6B in debt and plans $35B-$39B in capital expenditures this year.

$METAMedAI 8/10

Meta Vs. Oracle: The Laggards of AI Capex Payback Velocity

Oracle (ORCL) and Meta (META) reported significant AI-related capital expenditures, with ORCL spending $28.5B and META $30.1B in their respective quarters, leading to negative free cash flow. ORCL's cloud revenue grew 121% YoY, while META's revenue rose 28%. META's ad business shows early AI ROI, but ORCL's cash flow timeline remains uncertain.

$ORCLMedAI 8/10

New VA program pledges to bring Alaska veterans more access to care. US lawmakers subpoenaed its contractor.

The U.S. VA is launching a new Electronic Health Record (EHR) system in Alaska on Oct. 24, promising improved veteran care. The program, already delayed, faces scrutiny due to cost overruns and a $17 billion no-bid contract extension to Oracle. House lawmakers subpoenaed Oracle's CEO and Chairman to testify on Dec. 10. Oracle's ties to former President Trump are under investigation.